The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients
Open accessAbstract
Epstein–Barr virus (EBV) is associated with several malignancies including nasopharyngeal carcinoma, a high incidence tumor in Chinese populations, in which tumor cells express the two EBV antigens EB nuclear antigen 1 (EBNA1) and latent membrane protein 2 (LMP2). Here, we report the phase I trial of a recombinant vaccinia virus, MVA-EL, which encodes an EBNA1/LMP2 fusion protein designed to boost T-cell immunity to these antigens. The vaccine was delivered to Hong Kong patients with nasopharyngeal carcinoma to determine a safe and immunogenic dose. The patients, all in remission more than 12 weeks after primary therapy, received three intradermal MVA-EL vaccinations at three weekly intervals, using five escalating dose levels between 5 × 107 and 5 × 108 plaque-forming unit (pfu). Blood samples were taken during prescreening, immediately before vaccination, one week afterward and at intervals up to one year later. Immunogenicity was tested by IFN-γ ELIspot assays using complete EBNA1 and LMP2 15-mer peptide mixes and known epitope peptides relevant to patient MHC type. Eighteen patients were treated, three per dose level one to four and six at the highest dose, without dose-limiting toxicity. T-cell responses to one or both vaccine antigens were increased in 15 of 18 patients and, in many cases, were mapped to known CD4 and CD8 epitopes in EBNA1 and/or LMP2. The range of these responses suggested a direct relationship with vaccine dose, with all six patients at the highest dose level giving strong EBNA1/LMP2 responses. We concluded that MVA-EL is both safe and immunogenic, allowing the highest dose to be forwarded to phase II studies examining clinical benefit. Cancer Res; 73(6); 1676–88. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213
Cited by
Chua, M. L. K., Wee, J. T. S., Hui, E. P., & Chan, A. T. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00055-0 · Cited by 1,236
Self-citationMelief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Epstein–Barr virus: more than 50 years old and still providing surprises
Young, L. S., Yap, L. F., & Murray, P. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.92 · Cited by 856
Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
Lee, A. W. M., Ma, B. B. Y., Ng, W. T., & Chan, A. T. C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.9347 · Cited by 796
Self-citationThe Immunology of Epstein-Barr Virus–Induced Disease
Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B., & Hislop, A. D. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112326 · Cited by 602
Self-citation
Metadata
- Authors
- Hui, E. P., Taylor, G. S., Jia, H., Ma, B. B. Y., Chan, S. L., Ho, R., Wong, W.-L., Wilson, S., Johnson, B. F., Edwards, C., Stocken, D. D., Rickinson, A. B., Steven, N. M., & Chan, A. T. C.
- Venue
- Cancer Research
- Published
- 2013-03-14
- Volume
- 73
- Issue
- 6
- Pages
- 1676-1688
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2110002578
- Cited by
- 207
- References
- 1
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-2448
- The paper
- Hui, E. P., Taylor, G. S., Jia, H., Ma, B. B. Y., Chan, S. L., Ho, R., Wong, W.-L., Wilson, S., Johnson, B. F., Edwards, C., Stocken, D. D., Rickinson, A. B., Steven, N. M., & Chan, A. T. C. (2013). Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-2448
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.